Prime moves up on Inc. Magazine’s Annual List of America’s Fastest-Growing Private Companies

For the 8th consecutive year, Prime appears on the Inc. 5000, ranking no. 1,073 with three-year revenue growth of 391 percent

August 14, 2019
Prime Therapeutics (Prime) improved its standing by more than 200 places – from 1,288 in 2018 to 1,073 in 2019 – in the 38th annual Inc. 5000, a ranking of the nation’s fastest-growing private companies by Inc. Magazine. This is the eighth straight year Prime has achieved this distinction. And since 2017 Prime has been part of a select group of companies on Inc. 5000’s “Honor Roll.” Fewer than a tenth of Inc. 5000 honorees to ever achieve this milestone.

The list includes the most successful American companies in the dynamic independent small businesses segment. Companies that made the list, on average, have grown six-fold since 2015.

“In a rapidly consolidating market, our superior partnership model is helping to drive consistent growth among our existing clients, new clients, and new markets,” said Rob Kelley, interim chief financial officer at Prime. “We should all be extremely proud of these results and understand that continued commitment to consumer-centric innovation and total drug management will continue to help us grow and climb in this ranking.”

The full list, including Prime’s company profile, is available and will publish in the September issue of Inc., a leading publication for entrepreneurs.

Related news

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Stories

July 18, 2024

Specialty drug trend forecasted to drop for employer groups, clinical experts say

Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend

Stories

July 16, 2024

Prime/Magellan Rx earns top score on the Disability Equality Index

For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion